This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Malignant neoplasm of other endocrine glands and related structures, including Hilmo
C3_ENDOCRINE_NAS_WIDE
No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
3 out of 7 registries used, show all original rules. |
193 |
4. Check minimum number of eventsNone |
193 |
5. Include endpointsNone |
193 |
6. Filter based on genotype QC (FinnGen only) |
178 |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE
Extra metadata
- First used in FinnGen datafreeze
- DF12
Similar endpoints
↥List of similar endpoints to
Malignant neoplasm of other endocrine glands and related structures, including Hilmo
based on the number of shared cases.
Similar with more cases:
- Malignant neoplasm of endocrine gland, including Hilmo
- Solid cancers, including Hilmo
- Malignant neoplasm, wide definition
- Malignant neoplasm, including Hilmo
- Any prescribed medicine buy
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded (different definition than used in FinnGen).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 178 | 102 | 76 |
| Unadjusted period prevalence (%) | 0.04 | 0.04 | 0.03 |
| Median age at first event (years) | 56.96 | 51.20 | 64.68 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 182
- Matched controls
- 1820
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
130
Kela drug reimbursment
Malignant tumour
+∞
57.4
52
*
H02AB02
ATC
dexamethasone; systemic
108.6
51.3
54
7
C75.0
ICD-10 Finland
Malignant neoplasm: Parathyroid gland
+∞
50.4
46
*
EP1AE
NOMESCO Finland
Neck ultrasound examination
15.4
46.4
45
38
JN4BD
NOMESCO Finland
Extensive body CT
12.0
30.1
33
33
C75.9
ICD-10 Finland
Malignant neoplasm: Endocrine gland, unspecified
+∞
30.0
28
*
A03FA01
ATC
metoclopramide; systemic, rectal
6.5
29.6
63
138
XX3DW
NOMESCO Finland
Time consuming IT work
11.1
29.2
34
37
A04AA02
ATC
granisetron; systemic, transdermal
+∞
26.7
25
*
C79.5
ICD-10 Finland
Secondary malignant neoplasm of bone and bone marrow
+∞
26.7
25
*
WF049
NOMESCO Finland
Radiotherapy of metastasis
+∞
26.7
25
*
H02AB09
ATC
hydrocortisone; systemic
33.2
25.5
33
12
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
150.7
25.3
26
*
JN4AD
NOMESCO Finland
Body CT examination
9.4
25.1
33
42
8010/3-C75.0
ICD-O-3
Carcinoma, NOS, of parathyroid gland
+∞
24.5
23
*
H03AA01
ATC
levothyroxine sodium; systemic
4.8
24.1
82
264
E21.09
ICD-10 Finland
Other primary hyperparathyroidism
44.9
22.4
27
7
C75.3
ICD-10 Finland
Malignant neoplasm: Pineal gland
+∞
22.3
21
*
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
22.3
21
*
Z51.5
ICD-10 Finland
Palliative care
9.3
21.5
28
35
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
20.2
19
*
WZC00
NOMESCO Finland
Treatment plan or consultation
4.2
20.1
88
334
C73.91
ICD-10 Finland
Papillary carcinoma of the thyroid gland (thyroid gland)
+∞
19.1
18
*
D35.2
ICD-10 Finland
Benign neoplasm: Pituitary gland
43.5
19.1
23
6
A04AA01
ATC
ondansetron; systemic, rectal
17.9
18.7
29
19
8260/3-C73.9
ICD-O-3
Papillary adenocarcinoma, NOS, of thyroid gland
+∞
18.0
17
*
E23.00
ICD-10 Finland
Panhypopituitarism
198.5
17.8
18
*
N02AA05
ATC
oxycodone; systemic
4.5
17.8
54
155
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
+∞
16.9
16
*
WX408
NOMESCO Finland
General anesthesy, balanced
3.9
16.9
69
245
BAA40
NOMESCO Finland
Unilateral lobectomy of thyroid gland
24.8
16.0
22
10
115
Kela drug reimbursment
Breast cancer
+∞
15.9
15
*
C75.1
ICD-10 Finland
Malignant neoplasm: Pituitary gland
+∞
15.9
15
*
8680/3-C75.5
ICD-O-3
Paraganglioma, NOS, of aortic body and other paraganglia
+∞
14.8
14
*
C61
ICD-10 Finland
Malignant neoplasm of prostate
+∞
14.8
14
*
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
14.8
14
*
L03AA13
ATC
pegfilgrastim; parenteral
162.5
14.7
15
*
ZXE10
NOMESCO Finland
More than one and less than three hours
3.3
14.3
87
392
BBA40
NOMESCO Finland
Subtotal parathyroidectomy
58.1
14.1
16
*
AAB00
NOMESCO Finland
Extirpation of intracranial lesion
37.2
13.8
17
5
AAE10
NOMESCO Finland
Transsphenoidal total or partial excision of intracranial lesion
43.6
13.4
16
*
101
Kela drug reimbursment
Anterior pituitary hypofunction
43.6
13.4
16
*
BBA30
NOMESCO Finland
Excision of lesion of parathyroid gland
75.3
12.8
14
*
C75.8
ICD-10 Finland
Malignant neoplasm: Pluriglandular involvement, unspecified
+∞
12.6
12
*
PJA12
NOMESCO Finland
Sentinel node biopsy
+∞
12.6
12
*
M05BX04
ATC
denosumab; parenteral
5.4
12.6
27
57
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
5.0
12.4
29
66
AA4CG
NOMESCO Finland
Extensive MRI examination of sella turcica with high intensity magnet
40.6
12.4
15
*
ZX120
NOMESCO Finland
Intravenous
5.3
12.3
27
58
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
18.0
11.9
18
11
WX404
NOMESCO Finland
Intravenous generell anesthesy
3.6
11.9
48
165
E83.50
ICD-10 Finland
Hypercalcemia
24.9
11.8
16
7
116
Kela drug reimbursment
Prostate cancer
+∞
11.6
11
*
YA1BD
NOMESCO Finland
Extensive CT examination of head and neck for dose design of radiotherapy
+∞
11.6
11
*
C73
ICD-10 Finland
Malignant neoplasm of thyroid gland
+∞
11.6
11
*
ZX090
NOMESCO Finland
Other technic of radiotherapy
127.8
11.6
12
*
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
15.2
11.2
18
13
WZC30
NOMESCO Finland
Teaching
3.6
10.8
41
135
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.9
10.8
78
376
Z31.5
ICD-10 Finland
Genetic counselling
5.9
10.7
20
37
104
Kela drug reimbursment
Thyroid insufficiency
4.6
10.6
27
66
WD115
NOMESCO Finland
Multiple cystostatic therapy of methastized malignancy
+∞
10.5
10
*
WD305
NOMESCO Finland
Simple therapy of methastized malignancy with biomodifiers
+∞
10.5
10
*
WF003
NOMESCO Finland
Adjuvant radiotherapy
+∞
10.5
10
*
WF002
NOMESCO Finland
Radical radiotherapy
42.6
10.1
12
*
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.6
9.9
37
120
J38.0
ICD-10 Finland
Paralysis of vocal cords and larynx
18.8
9.6
14
8
YA1AD
NOMESCO Finland
CT examination of head and neck for dose design of radiotherapy
+∞
9.5
9
*
WF004
NOMESCO Finland
Palliative radiotherapy
+∞
9.5
9
*
L01BC06
ATC
capecitabine; oral
+∞
9.5
9
*
A04AA55
ATC
palonosetron, combinations; systemic
+∞
9.5
9
*
D35.59
ICD-10 Finland
Other paragangliom
+∞
9.5
9
*
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
13.5
9.0
15
12
ZXD10
NOMESCO Finland
Scheduled procedure
2.6
8.7
80
426
D44.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Thyroid gland
29.1
8.6
11
*
L03AA02
ATC
filgrastim; parenteral
94.2
8.5
9
*
C50.41
ICD-10 Finland
Malignant tumor of the upper outer quadrant of the mammary gland, ductal tumor
+∞
8.4
8
*
C75.2
ICD-10 Finland
Malignant neoplasm: Craniopharyngeal duct
+∞
8.4
8
*
YG1BD
NOMESCO Finland
Extensive CT examination of thorax for dose design of radiotherapy
+∞
8.4
8
*
E21.3
ICD-10 Finland
Hyperparathyroidism, unspecified
15.4
8.3
13
9
ZXE00
NOMESCO Finland
One hour or less
2.5
8.3
84
466
H01BA02
ATC
desmopressin; nasal, systemic, sublingual
9.6
8.2
16
18
L02BG04
ATC
letrozole; oral
13.9
8.0
13
10
R50.9
ICD-10 Finland
Fever, unspecified
3.0
7.7
39
151
ZXE20
NOMESCO Finland
More than three and less than five hours
3.2
7.6
34
123
WX402
NOMESCO Finland
General anaesthesia
2.8
7.6
47
204
AAB10
NOMESCO Finland
Partial excision of intracranial lesion
83.3
7.5
8
*
C64.88
ICD-10 Finland
Other malignant neoplasm of kidney, except renal pelvis
+∞
7.3
7
*
C75.5
ICD-10 Finland
Malignant neoplasm: Aortic body and other paraganglia
+∞
7.3
7
*
E23.2
ICD-10 Finland
Diabetes insipidus
+∞
7.3
7
*
YL1AD
NOMESCO Finland
CT examination of pelvis for dose design of radiotherapy
+∞
7.3
7
*
C50.99
ICD-10 Finland
Breast, unspecified
+∞
7.3
7
*
YA1VG
NOMESCO Finland
MRI examination of head and neck with high intesity magnet for dose design of radiotherapy
+∞
7.3
7
*
YX9AD
NOMESCO Finland
Other CT eamination for dose design of radiotherapy
+∞
7.3
7
*
C78.7
ICD-10 Finland
Secondary malignant neoplasm of liver and intrahepatic bile duct
+∞
7.3
7
*
WD405
NOMESCO Finland
Simple antiboidy therapy of methastized malignancy
+∞
7.3
7
*
8272/3-C75.1
ICD-O-3
Pituitary carcinoma, NOS, of pituitary gland
+∞
7.3
7
*
ZX070
NOMESCO Finland
Intensity modified radiotherapy
+∞
7.3
7
*
HAC20
NOMESCO Finland
Total mastectomy
+∞
7.3
7
*
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
12.7
7.2
12
10
102
Kela drug reimbursment
Diabetes insipidus
41.6
6.8
8
*
321
Kela drug reimbursment
Paricalcitol and cinacalcet
41.6
6.8
8
*
EP1CG
NOMESCO Finland
Extensive MRI examination of soft tissue of neck with high intesity magnet
41.6
6.8
8
*
L02BA01
ATC
tamoxifen; oral
41.6
6.8
8
*
E34.9
ICD-10 Finland
Endocrine disorder, unspecified
23.5
6.7
9
*
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
5.6
6.5
18
35
HA1AE
NOMESCO Finland
Ultrasound examination of mammary glands
7.0
6.5
15
23
D35.1
ICD-10 Finland
Benign neoplasm: Parathyroid gland
72.3
6.5
7
*
BBA20
NOMESCO Finland
Exploration of parathyroid gland
72.3
6.5
7
*
BB1BQ
NOMESCO Finland
Extensive scintigraphy of parathyroid gland, 2 isotopes, SPECT and low-dose CT
72.3
6.5
7
*
WD205
NOMESCO Finland
Therapy of methastized malignancy with hormones
+∞
6.3
6
*
8140/3-C75.0
ICD-O-3
Adenocarcinoma, NOS, of parathyroid gland
+∞
6.3
6
*
C74.1
ICD-10 Finland
Malignant neoplasm: Medulla of adrenal gland
+∞
6.3
6
*
C74.0
ICD-10 Finland
Malignant neoplasm: Cortex of adrenal gland
+∞
6.3
6
*
WD505
NOMESCO Finland
Simple enzyme inhibitor or similar therapy of methastized malignancy
+∞
6.3
6
*
C79.30
ICD-10 Finland
Secondary malignant tumor of the cerebrum
+∞
6.3
6
*
YL1BD
NOMESCO Finland
Extensive CT examination of pelvis for dose design of radiotherapy
+∞
6.3
6
*
ZX050
NOMESCO Finland
Stereotactic radiotherapy
+∞
6.3
6
*
D35.50
ICD-10 Finland
Carotid body
+∞
6.3
6
*
C73, C75,
ICD-10 Finland
+∞
6.3
6
*
C71.99
ICD-10 Finland
Malignant tumor in unspecified localization in the brain other or unspecified histology
+∞
6.3
6
*
Y77
ICPC
Malignant neoplasm prostate
+∞
6.3
6
*
L01AX03
ATC
temozolomide; systemic
+∞
6.3
6
*
C78.0
ICD-10 Finland
Secondary malignant neoplasm of lung
+∞
6.3
6
*
166
Kela drug reimbursment
Dalteparin and tinzaparin (treatment for more than 6 months)
+∞
6.3
6
*
L02BG06
ATC
exemestane; oral
+∞
6.3
6
*
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
+∞
6.3
6
*
ZXC86
NOMESCO Finland
Use of endoscopic device
27.7
6.3
8
*
H05BX01
ATC
cinacalcet; oral
27.7
6.3
8
*
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
13.1
6.2
10
8
BA3AT
NOMESCO Finland
Cytology of thyroid with ultrasound quidance
13.1
6.2
10
8
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
46
104
5.58
20.30
6.6
2.8
1.22
1.23
mmol/l
0.32
41
85
46
143
3.97
13.29
4.0
3.0
—
—
—
0
0
118
664
3.21
12.85
15.2
5.9
1.22
1.21
mmol/l
0.62
113
607
124
756
3.01
11.02
15.8
6.1
1.23
1.21
mmol/l
0.75
95
661
18
17
11.61
10.04
4.1
1.3
94.01
25.51
ng/l
0.54
18
17
36
114
3.69
9.97
9.4
3.1
112.73
85.05
ng/l
0.55
30
98
13
5
27.80
9.96
6.4
4.4
1.91
1.56
ug/l
—
13
5
16
19
9.12
8.00
1.3
1.3
—
—
—
0
0
23
67
3.78
7.11
2.1
1.3
18.08
19.89
iu/l
0.10
17
57
15
22
7.33
6.67
3.1
3.3
5.49
10.62
pmol/l
1.16
15
22
25
82
3.38
6.48
9.4
8.4
24.85
24.98
mmol/l
0.07
25
82
16
33
5.21
5.58
3.1
1.5
—
—
—
0
0
128
1531
0.45
5.38
5.7
6.0
2.61
2.66
mmol/l
0.31
119
1436
126
1514
0.45
5.30
5.1
5.3
4.49
4.57
mmol/l
0.37
119
1422
95
634
2.04
5.29
7.2
3.7
34.69
36.16
g/l
1.37
89
596
125
1506
0.46
5.28
5.0
5.2
1.39
1.47
mmol/l
1.60
117
1406
116
1434
0.47
5.25
4.2
4.4
1.44
1.25
mmol/l
2.00
108
1323
5
0
+∞
5.23
13.8
0.0
168.00
—
u/ml
—
5
0
8
6
13.86
5.13
1.1
1.8
—
—
—
0
0
8
6
13.86
5.13
2.4
1.5
57.13
58.50
nmol/l
—
8
6
12
20
6.34
5.00
3.6
1.7
4.85
4.74
kpa
0.19
12
20
23
96
2.60
3.91
9.0
10.2
96.13
92.77
%
3.76
23
96
66
425
1.87
3.79
3.4
2.8
0.78
0.36
e6/l
0.41
56
296
90
646
1.78
3.57
3.5
2.5
—
—
estimate
—
0
0
7
10
7.23
3.39
2.6
1.0
104.57
113.30
pmol/l
—
7
10
32
172
2.04
3.06
7.2
10.4
1.10
1.24
mmol/l
0.06
26
151
12
37
3.40
2.99
2.7
2.2
15.23
15.83
u/ml
0.06
12
29
8
19
4.35
2.71
1.1
1.2
—
—
—
0
0
105
829
1.63
2.64
19.0
5.8
4.21
4.29
e9/l
0.13
96
716
12
42
2.99
2.60
5.5
1.9
1.40
1.33
mg/l
0.11
12
35
5
7
7.30
2.56
1.2
2.4
—
—
—
0
0
6
11
5.60
2.56
1.0
1.0
—
—
—
0
0
6
11
5.60
2.56
1.2
1.2
—
—
—
0
0
6
11
5.60
2.56
1.8
1.8
—
—
—
0
0
10
31
3.35
2.56
1.4
2.1
88.80
91.77
%
—
10
31
9
27
3.45
2.43
1.8
2.6
3.44
4.03
g/l
—
9
27
12
46
2.72
2.41
1.2
1.2
—
—
—
0
0
7
17
4.24
2.38
6.1
1.4
3.37
219.86
u/ml
—
7
17
11
40
2.86
2.32
1.3
1.3
387.60
287.65
ug/g
—
5
19
21
107
2.09
2.31
1.7
1.5
—
—
—
0
0
154
1660
0.53
2.26
44.7
20.3
4.41
4.51
e12/l
1.26
149
1617
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
10
35
2.96
2.24
1.8
1.9
0.42
0.43
iu/ml
—
5
19
135
1158
1.64
2.23
16.1
5.3
91.69
76.12
u/l
2.02
130
1080
39
254
1.68
2.04
1.8
1.6
—
—
—
0
0
5
11
4.64
1.95
1.6
1.3
2.11
4.63
ug/l
—
5
11
5
11
4.64
1.95
1.0
1.0
—
—
—
0
0
47
325
1.60
1.95
3.0
2.1
—
—
—
0
0
18
94
2.02
1.88
11.9
3.1
24.22
24.51
mmol/l
0.08
18
94
149
1608
0.60
1.82
18.8
9.8
27.28
24.93
u/l
1.08
141
1555
11
47
2.43
1.81
1.7
1.3
7.23
2.96
ug/l
0.47
11
39
136
1497
0.64
1.78
5.7
5.1
5.93
5.97
mmol/l
0.17
125
1378
0
48
0.00
1.72
0.0
1.3
—
—
—
0
0
131
1450
0.66
1.71
7.6
6.9
41.09
39.87
mmol/mol
0.66
122
1373
7
26
2.76
1.59
1.1
1.2
—
—
—
0
0
58
440
1.47
1.55
4.9
3.7
0.00
0.00
estimate
-0.00
28
141
5
15
3.40
1.53
1.4
1.4
—
—
—
0
0
7
28
2.56
1.46
1.1
1.3
—
—
—
0
0
86
723
1.36
1.23
3.9
2.5
73.10
77.68
nmol/l
0.95
79
650
62
495
1.38
1.23
4.3
2.4
56.16
65.14
u/l
0.40
56
456
6
26
2.35
1.19
1.3
1.3
—
—
—
0
0
26
178
1.54
1.13
1.9
1.6
—
—
—
0
0
133
1207
1.38
1.11
8.8
4.3
15.45
14.77
pmol/l
2.21
128
1109
27
189
1.50
1.07
1.7
1.5
—
—
—
0
0
53
423
1.36
1.04
2.9
2.3
2.96
2.81
mg/l
0.21
47
361
0
32
0.00
0.96
0.0
1.5
—
—
—
0
0
6
27
2.26
0.94
1.2
1.7
—
—
—
0
0
6
27
2.26
0.94
1.0
1.4
—
—
—
0
0
7
127
0.53
0.92
2.6
2.5
—
12.98
—
0
11
34
263
1.36
0.81
3.0
2.5
108.17
1.22
e6/l
0.48
15
124
41
328
1.32
0.79
2.1
1.8
540.91
431.56
pmol/l
0.72
32
275
0
28
0.00
0.76
0.0
1.7
—
—
—
0
0
14
92
1.57
0.75
10.4
2.5
0.56
0.60
%
0.29
14
92
6
110
0.53
0.74
1.2
1.3
—
29.73
—
0
12
7
38
1.88
0.74
1.4
3.2
—
—
—
0
0
46
378
1.29
0.73
3.7
2.3
349.11
342.92
umol/l
0.15
36
327
22
293
0.72
0.72
1.4
1.3
1.73
10.64
u/ml
—
9
113
9
57
1.61
0.72
1.0
1.2
—
—
—
0
0
14
93
1.55
0.72
10.4
2.5
1.14
1.32
%
0.24
14
93
9
58
1.58
0.71
1.0
1.2
—
—
—
0
0
24
313
0.73
0.69
1.4
1.3
14.29
36.27
iu/ml
—
7
100
7
42
1.69
0.69
3.6
1.3
0.00
0.00
g/l
—
7
36
137
1447
0.78
0.67
9.3
5.4
1.60
1.87
mu/l
1.74
129
1338
5
28
1.81
0.66
1.2
1.3
—
—
—
0
0
5
28
1.81
0.66
1.2
1.3
—
—
—
0
0
14
95
1.51
0.66
1.1
1.3
58.39
113.84
u/ml
—
8
39
7
44
1.61
0.66
1.1
1.2
—
—
—
0
0
85
759
1.22
0.66
4.5
3.0
221.63
113.12
ug/l
0.81
78
713
41
341
1.26
0.60
1.5
1.8
1.78
1.21
mg/l
0.45
26
274
13
89
1.50
0.60
1.8
1.4
—
—
—
0
0
34
279
1.27
0.55
2.3
1.7
1304.58
1121.99
nmol/l
0.38
24
222
10
66
1.55
0.53
1.1
1.6
—
—
—
0
0
24
294
0.79
0.46
1.3
1.8
—
—
—
0
0
7
51
1.39
0.44
3.6
1.2
11.57
10.36
g/l
—
7
45
13
172
0.74
0.43
1.8
2.2
—
—
—
0
0
8
59
1.37
0.41
1.4
1.5
—
—
—
0
0
0
16
0.00
0.41
0.0
1.1
—
—
—
0
0
0
17
0.00
0.41
0.0
4.1
—
24.38
—
0
8
0
18
0.00
0.40
0.0
1.4
—
—
—
0
0
0
18
0.00
0.40
0.0
1.2
—
—
—
0
0
92
856
1.15
0.39
4.6
3.7
0.00
0.00
estimate
-0.00
29
148
69
753
0.87
0.39
2.1
2.1
88.88
95.79
pmol/l
0.76
43
376
91
847
1.15
0.38
4.5
3.7
0.00
0.00
estimate
-0.00
32
156
29
246
1.21
0.37
3.1
2.7
0.70
4.06
e6/l
—
9
107
14
108
1.32
0.36
7.3
2.0
85.14
67.52
ml/min/173m2
—
7
44
15
189
0.78
0.36
1.7
2.4
—
—
—
0
0
35
398
0.85
0.33
1.2
1.4
0.80
1.80
u/ml
—
8
106
12
152
0.77
0.31
1.9
2.5
3.52
7.50
ug/l
0.89
12
137
7
54
1.31
0.31
3.6
1.2
2.59
2.93
g/l
—
7
48
7
57
1.24
0.29
3.6
1.2
6.94
7.57
g/l
—
7
51
7
57
1.24
0.29
3.6
1.2
3.21
3.71
g/l
—
7
51
7
57
1.24
0.29
3.6
1.2
4.00
4.21
g/l
—
7
51
8
62
1.30
0.28
1.4
1.5
—
—
—
0
0
89
840
1.12
0.28
4.6
3.6
0.00
0.00
estimate
-0.00
31
158
141
1451
0.87
0.27
30.3
12.6
79.31
80.67
ml/min/173m2
0.26
131
1327
60
644
0.90
0.25
5.0
3.9
29.15
87.94
ng/l
0.56
49
450
45
489
0.89
0.23
2.0
1.7
17.18
20.33
nmol/l
1.03
39
417
148
1513
0.88
0.22
26.4
13.5
26.13
22.38
mg/l
0.77
137
1211
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
127.35
—
0
10
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
91
950
0.92
0.20
3.1
3.2
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
68
649
1.08
0.15
5.0
3.6
0.00
0.00
estimate
-0.00
28
125
69
662
1.07
0.13
1.9
2.0
1.57
1.31
mmol/l
1.40
53
569
10
114
0.87
0.10
1.7
1.4
—
—
—
0
0
50
479
1.06
0.09
4.1
3.1
0.00
0.00
estimate
-0.00
25
120
36
377
0.94
0.08
5.2
3.8
1.02
1.02
kg/l
0.97
23
241
48
497
0.95
0.07
3.3
3.1
4374.51
1277.86
ng/l
0.43
41
423
9
101
0.89
0.06
1.0
1.0
—
—
—
0
0
16
172
0.92
0.06
10.9
6.6
—
—
—
0
0
105
1039
1.03
0.03
3.5
3.2
66.05
42.33
u/l
1.79
99
981
57
577
0.98
0.01
5.1
4.2
22.95
7.62
mg/mmol
0.85
39
368
118
1173
1.02
0.01
4.7
4.2
12.85
11.31
mm/h
0.48
113
1077
10
96
1.04
0.00
1.0
1.3
—
—
—
0
0
23
229
1.00
0.00
1.3
1.5
—
—
—
0
0
25
249
1.00
0.00
3.6
2.7
0.77
0.76
ug/l
0.01
17
157
35
349
1.00
0.00
8.2
3.8
23.69
24.79
%
0.16
16
159
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
0.34
—
0
5
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
7.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.7
—
65.94
—
0
7
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
5
52
0.96
-0.00
1.2
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
5
49
1.02
-0.00
1.2
1.2
—
3.48
—
0
8
8
82
0.97
-0.00
1.4
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
81.72
—
0
5
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
10.54
—
0
6
Mortality – FinRegistry
↥This endpoint is excluded (different definition than used in FinnGen).
Relationships between endpoints
↥Index endpoint: C3_ENDOCRINE_NAS_WIDE – Malignant neoplasm of other endocrine glands and related structures, including Hilmo
GWS hits: -
This endpoint is excluded (different definition than used in FinnGen).